Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear
Somatic 9p24.1 copy number alterations predicted the degree to which HPV-negative advanced squamous head and neck cancers benefitted from Keytruda and Opdivo.
New data suggests that immunotherapy treatment informed by a multi-factorial consideration of tumor features can effectively identify patients most likely to respond.
BillionToOne, UCSD Partner to Assess New Liquid Biopsy Assays in Lung Cancer
Investigators are evaluating the firm's tumor profiling and treatment response monitoring assays and expect initial results in a few months.
Pan-Cancer Analyses Reveal Copy Number Signatures, Chromosomal Instability Patterns
Investigators identified up to 21 copy number signatures in cross-cancer analyses, including potential disease response markers and signatures linked to chromosomal instability features.
TROPiCS-02 Trial Sees Progression-Free Survival Edge for Trodelvy-Treated Advanced Breast Cancers
The antibody-drug conjugate stretched out time to progression in a Phase III trial of pretreated patients with advanced hormone receptor-positive, HER2-negative breast cancers.